Ensemble disease gene prediction by clinical sample-based networks

GediNET for discovering gene associations across diseases using knowledge based machine learning approach

The most common approaches to discovering genes associated with specific diseases are based on machine learning and use a variety of feature selection techniques to identify significant genes that can serve as biomarkers for a given disease. More recently, the integration in this process of prior knowledge-based approaches has shown significant promise in the discovery of new biomarkers with potential translational applications. In this study, we developed a novel approach, GediNET, that integrates prior biological knowledge to gene Groups that are shown to be associated with a specific disease such as a cancer. The novelty of GediNET is that it then also allows the discovery of significant associations between that specific disease and other diseases. The initial step in this process involves the identification of gene Groups. The Groups are then subjected to a Scoring component to identify the top performing classification Groups. The top-ranked gene Groups are then used to train a Machine Learning Model. The process of Grouping, Scoring and Modelling (G-S-M) is used by GediNET to identify other diseases that are similarly associated with this signature. GediNET identifies these relationships through Disease-Disease Association (DDA) based machine learning. DDA explores novel associations between diseases and identifies relationships which could be used to further improve approaches to diagnosis, prognosis, and treatment. The GediNET KNIME workflow can be downloaded from: https://github.com/malikyousef/GediNET.git or https://kni.me/w/3kH1SQV_mMUsMTS .

M2PP: a novel computational model for predicting drug-targeted pathogenic proteins

BACKGROUND

Detecting pathogenic proteins is the origin way to understand the mechanism and resist the invasion of diseases, making pathogenic protein prediction develop into an urgent problem to be solved. Prediction for genome-wide proteins may be not necessarily conducive to rapidly cure diseases as developing new drugs specifically for the predicted pathogenic protein always need major expenditures on time and cost. In order to facilitate disease treatment, computational method to predict pathogenic proteins which are targeted by existing drugs should be exploited.

RESULTS

In this study, we proposed a novel computational model to predict drug-targeted pathogenic proteins, named as M2PP. Three types of features were presented on our constructed heterogeneous network (including target proteins, diseases and drugs), which were based on the neighborhood similarity information, drug-inferred information and path information. Then, a random forest regression model was trained to score unconfirmed target-disease pairs. Five-fold cross-validation experiment was implemented to evaluate model's prediction performance, where M2PP achieved advantageous results compared with other state-of-the-art methods. In addition, M2PP accurately predicted high ranked pathogenic proteins for common diseases with public biomedical literature as supporting evidence, indicating its excellent ability.

CONCLUSIONS

M2PP is an effective and accurate model to predict drug-targeted pathogenic proteins, which could provide convenience for the future biological researches.

Main findings and advances in bioinformatics and biomedical engineering- IWBBIO 2018

In the current supplement, we are proud to present seventeen relevant contributions from the 6th International Work-Conference on Bioinformatics and Biomedical Engineering (IWBBIO 2018), which was held during April 25-27, 2018 in Granada (Spain). These contributions have been chosen because of their quality and the importance of their findings.